Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06713564 · ClinicalTrials.gov registry record · Phase 1
A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer
A Phase 1 study of Lung Cancers, sponsored by Integro Theranostics.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06713564 is a Phase 1 study of Lung Cancers that is active but no longer recruiting, run by Integro Theranostics. The registered enrollment target is 24 participants, below the 177-participant average among 5 other Lung Cancers trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06713564, a Phase 1 study of Lung Cancers, is active but no longer recruiting, sponsored by Integro Theranostics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by slow intravenous (IV) administration in patients undergoing surgical thoracoscopy and resection of lung cancer. Safety is the primary objective of this study, followed by the evaluation of the fluorescence signal as it relates to dose level and dosing time interval.
Conditions Studied
Interventions
- DRUG LS301-IT
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-11-07 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06713564
The ClinicalTrials.gov registry entry for NCT06713564 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 5 other Lung Cancers trials with a reported enrollment target (86% lower). The listed sponsor is Integro Theranostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancers appearing as the primary indexed condition, and to 1 intervention - of which LS301-IT is the first listed.
NCT06713564 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06713564 about?
NCT06713564 is a clinical study titled "A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer". The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by slow intravenous (IV) administration in patients undergoing surgical thoracoscopy and resection...
What is the current status of trial NCT06713564?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-11-07. Estimated completion is 2026-03.
What conditions does trial NCT06713564 study?
This clinical trial studies the following conditions: Lung Cancers.
What interventions are being tested in trial NCT06713564?
The interventions under investigation include: LS301-IT (DRUG).
Who is sponsoring clinical trial NCT06713564?
This trial is sponsored by Integro Theranostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06713564 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RECRUITING · Phase 1
-
Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery
RECRUITING · Phase 3
-
Rapid Autopsy and Procurement of Cancer Tissue
RECRUITING
-
Bright Light Therapy on Sleep Health in Lung Cancer Patients
RECRUITING · NA
-
Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.